<SEC-DOCUMENT>0001558370-16-008371.txt : 20160919
<SEC-HEADER>0001558370-16-008371.hdr.sgml : 20160919
<ACCEPTANCE-DATETIME>20160919090124
ACCESSION NUMBER:		0001558370-16-008371
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160916
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160919
DATE AS OF CHANGE:		20160919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AxoGen, Inc.
		CENTRAL INDEX KEY:			0000805928
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				411301878
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36046
		FILM NUMBER:		161890854

	BUSINESS ADDRESS:	
		STREET 1:		13859 PROGRESS BLVD.
		STREET 2:		SUITE 100
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615
		BUSINESS PHONE:		(386) 462-6817

	MAIL ADDRESS:	
		STREET 1:		13859 PROGRESS BLVD.
		STREET 2:		SUITE 100
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LECTEC CORP /MN/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>axgn-20160916x8k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Merrill Bridge  6.2.143.0-->
<!--Created on: 9/19/2016 8:00:08 AM-->
<html>
	<head>
		<title>
			axgn_Current_Folio_8K
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt solid #000000 ;border-bottom:1pt solid #000000 ;line-height:1pt;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 13pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:13.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 13pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:13.5pt;">UNITED STATES </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 13pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:13.5pt;">SECURITIES AND EXCHANGE COMMISSION </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Washington, D.C. 20549 </font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 18pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:18pt;">Form 8-K</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">Current Report </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Date of Report (Date of earliest event reported):&nbsp; September 16, 2016</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 18pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:18pt;">AXOGEN, INC. </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Exact name of registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:32.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Minnesota</font></p>
				</td>
				<td valign="top" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:32.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">001-36046</font></p>
				</td>
				<td valign="top" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:32.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">41-1301878</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:32.00%;padding:0pt;">
					<p style="margin:0pt;text-indent: -12.25pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(State or other jurisdiction of<br /></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">incorporation)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:32.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Commission File Number)</font></p>
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(IRS Employer</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Identification No.)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:48.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:48.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">13631 Progress Boulevard, Suite 400,</font></p>
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Alachua, Florida</font></p>
				</td>
				<td valign="top" style="width:04.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:48.00%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">32615</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(Address of Principal Executive Offices)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:48.00%;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(Zip Code)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Registrant&#x2019;s telephone number, including area code</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 53.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(386) 462-6800</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Former name or former address if changed since last report,)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7.5pt;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br /><br /></font><font style="display:inline;color:#000000;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br /><br /></font><font style="display:inline;color:#000000;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br /><br /></font><font style="display:inline;color:#000000;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 13pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:13.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt solid #000000 ;border-bottom:3pt solid #000000 ;line-height:1pt;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:11pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:11pt;">Item 5.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">On September 16, 2016, &nbsp;Joseph Mandato submitted to AxoGen, Inc. (the &#x201C;Company&#x201D;)&nbsp;his letter of resignation (the &#x201C;Letter of Resignation&#x201D;) as a member of the Board of Directors (the &#x201C;Board&#x201D;) of the Company, effective immediately. &nbsp; A copy of the Letter of Resignation is filed herewith as Exhibit 17.1.  The Board accepted Mr. Mandato&#x2019;s Letter of Resignation and thanked him for his long and valued service on the Board. The Company notes that Mr. Mandato&#x2019;s resignation was not the result of any disagreement with the Company relating to the Company&#x2019;s operations, policies or practices. Mr. Mandato served on the AxoGen Corporation (&#x201C;AC&#x201D;) board of directors from February 2006 until AC&#x2019;s merger with and into the Company in September 2011, and served on the Board since such merger. &nbsp;Mr. Mandato has served on the Company&#x2019;s Governance and Nominating Committee since December 2015.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">Based on the recommendation of, and nomination by, the Company&#x2019;s Governance and Nominating Committee, Amy Wendell was appointed to the Board to fill the vacancy on the Board resulting from Mr. Mandato&#x2019;s resignation, effective September 16, 2016.&nbsp;&nbsp;Additionally, as a result of Mr. Mandato&#x2019;s resignation, the Board reviewed the composition of its committees and determined to have Ms. Wendell appointed to the Governance and Nominating and Compensation Committee, effective September 16, 2016.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">Ms. Wendell, age 55, has been a senior advisor for Perella Weinberg Partners&#x2019; (&#x201C;PWP&#x201D;) healthcare investment banking practice since January 2016.&nbsp;&nbsp;Her scope of responsibilities involves providing guidance and advice with respect to mergers and acquisitions and divestitures for clients, and assisting PWP in connection with firm-level transactions.&nbsp;&nbsp;Since 2015, Ms. Wendell has also been a senior advisor for McKinsey and Company&#x2019;s (&#x201C;McKinsey&#x201D;) strategy and corporate finance practice and also serves as a member of McKinsey's transactions advisory board to help define trends in mergers and acquisitions, as well as help shape McKinsey's knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (&#x201C;Covidien&#x201D;) (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including in engineering, product management and business development. Most recently, from December 2006 until Covidien&#x2019;s acquisition by Medtronic plc in January 2015, Ms. Wendell served as Covidien&#x2019;s senior vice president of strategy and business development, where she managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution, and led Covidien&#x2019;s strategy and portfolio management initiatives. Ms. Wendell is a member of the board of directors of Ekso Bionics [OTCBB: EKSO], which develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of soldiers and paraplegics.&nbsp;&nbsp;Ms. Wendell is also a director of Por Cristo, a non-profit charitable medical service organization involved in health care work for at-risk women and children in Latin America.&nbsp;&nbsp;Ms. Wendell holds a Bachelor of Science degree in mechanical engineering from Lawrence Institute of Technology (n/k/a Lawrence Technological University) and a Master of Science degree in biomedical engineering from the University of Illinois.&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">The Company believes Ms. Wendell has the requisite qualifications, skills and perspectives to be a valuable member of the Board based on, among other things, her broad healthcare management and governance experience, and her knowledge of healthcare policy and regulation, patient care delivery and financing, as well as her knowledge of clinical research and medical technology assessment.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">There is no arrangement or understanding between Ms. &nbsp;Wendell and any other person pursuant to which Ms. Wendell was appointed as a director of the Company. There are no transactions in which Ms. &nbsp;Wendell has an interest requiring disclosure under Item 404(a) of Regulation S-K. Ms. &nbsp;Wendell will receive the director compensation that is awarded to all non-employee directors for their service on the Board and the Governance and Nominating Committee.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">On September 19, 2016, the Company issued a press release announcing Mr. Mandato&#x2019;s resignation from, and Ms. Wendell&#x2019;s appointment to, the Board. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:11pt;">Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">(d)&nbsp;&nbsp;Exhibits</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 26.65pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Letter of Resignation of Joseph Mandato, filed herewith.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 26.65pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release, dated September 19, 2016.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:11pt;">SIGNATURE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:49.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">AXOGEN, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.46%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.56%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">/s/ Gregory G. Freitag</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.46%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.56%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Gregory G. Freitag</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.46%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.56%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">General Counsel and SVP Business Development</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.46%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Date:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.56%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">September 19, 2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-17.1
<SEQUENCE>2
<FILENAME>axgn-20160916ex17159e34d.htm
<DESCRIPTION>EX-17.1
<TEXT>
<!--HTML document created with Merrill Bridge  6.2.143.0-->
<!--Created on: 9/19/2016 8:00:12 AM-->
<html>
	<head>
		<title>
			axgn_EX17_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 0pt 144pt;text-align:right;border-bottom:1pt none #D9D9D9 ;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">EXHIBIT 17.1</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">Joe Mandato</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">765 Market Street, #29D </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">San Francisco 94103</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">To:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jamie Grooms &#x2013; Chairman of the Board - Axogen, Inc.</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">From:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joe Mandato</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-size:5pt;">&nbsp;</font><font style="display:inline;">9-16-2016</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">Subject:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resignation</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">Please be advised that I hereby resign from the board of directors&nbsp;effective September 16, 2016.&nbsp; My decision is not the result of any disagreement with AxoGen relating to its operations, policies or practices.&nbsp; I have enjoyed a long relationship with AxoGen and look forward to continue to watch its success. It has been a pleasure to work with the company, its management team and its board of directors.&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">Sincerely,</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">/s/Joe Mandato</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">Joe Mandato </font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Cambria;font-size: 12pt;">
			<font style="display:inline;">CC: Dr. Mark Gold, &nbsp;Greg Freitag, Karen Zaderej</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>axgn-20160916ex991b54ee5.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Merrill Bridge  6.2.143.0-->
<!--Created on: 9/19/2016 8:00:16 AM-->
<html>
	<head>
		<title>
			axgn_EX99_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt;line-height:115%;border-bottom-style:solid;border-bottom-width:1pt;font-family:Calibri;color:#000000;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"><img src="axgn20160916ex991b54ee5001.jpg" style="width: 2.240221in; height: 0.7318428in" alt="officeArt object"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 16pt;">
			<font style="display:inline;font-family:Calibri;font-size:16pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 16pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:16pt;">AxoGen, Inc. Appoints&nbsp;Amy Wendell to Board of Directors</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-style:italic;">Former Covidien Senior Executive Brings More Than 30 Years of Experience to AxoGen Board</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">ALACHUA, FL &#x2013; September 19, 2016 &#x2013;</font><font style="display:inline;font-family:Calibri;"> AxoGen, Inc. (NASDAQ: AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced the election of Amy Wendell to its Board of Directors effective September 16, 2016. &nbsp;Ms. Wendell was also appointed to the Company&#x2019;s Compensation and Governance Committees.&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&#x201C;Amy brings a wealth of proven healthcare experience in market and technology development as well as operating leadership,&#x201D; commented Karen Zaderej, President and Chief Executive Officer.&nbsp;&nbsp;&#x201C;I am delighted Amy is joining the AxoGen Board of Directors and look forward to her partnership as we continue to&nbsp;develop the peripheral nerve repair market and AxoGen products become the preeminent choice of surgeons.&#x201D;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Most recently, Amy Wendell served as Covidien&#x2019;s Senior Vice President of Strategy and Business Development where she led the company&#x2019;s strategic planning and portfolio management functions, including licensing, distribution and market intelligence.&nbsp;&nbsp;Ms. Wendell&nbsp;joined Covidien, formerly known as Tyco Healthcare/Kendall, in 1986 and she held roles of increasing responsibility up through&nbsp;its acquisition by Medtronic (NYSE: MDT) in January 2015.&nbsp; Since 2015, Ms. Wendell has been a Senior Advisor for McKinsey&#x2019;s Strategy and Corporate Finance Practice and also serves as a member of McKinsey's Transactions Advisory Board.&nbsp; Since January 2016, Ms. Wendell has also been a Senior Advisor for Perella Weinberg Partners&#x2019; Healthcare Investment Banking Practice. &nbsp; &nbsp;Ms. Wendell is also a member of the board of directors of Ekso Bionics (NASDAQ: EKSO), and&nbsp;Por Cristo, a non-profit organization.&nbsp;&nbsp;Ms. Wendell holds a Bachelor of Science degree in Mechanical Engineering from Lawrence Technological University and a Master of Science degree in Biomedical Engineering from the University of Illinois.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&#x201C;I am honored to join the AxoGen board at such an exciting time in its history&nbsp;and I &nbsp;look forward to&nbsp;contributing to the continued expansion of the business.&#x201D;&nbsp;said Ms. &nbsp;Wendell. &nbsp;&#x201C;AxoGen has built an impressive team&nbsp;and has a tremendous opportunity to drive greater awareness and improved solutions for patients faced with potentially debilitating nerve injuries.&#x201D;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Ms. Wendell has been elected to the board following the resignation of Joe Mandato&nbsp;from the Company's board of directors,&nbsp;which is also effective September 16, 2016. &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">"On behalf of our board of directors, I want thank Joe for his 10 years of service and contributions to AxoGen," commented Ms. Zaderej.&nbsp;&#x201C;Joe&#x2019;s &nbsp;guidance &nbsp;-&nbsp;from AxoGen&#x2019;s initial funding to our current position of growth - has been invaluable in helping AxoGen become a global leader in peripheral nerve repair.&#x201D;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;"><font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">About AxoGen, Inc.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">AxoGen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen&#x2019;s portfolio of products includes Avance&#xAE; Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard&#xAE; Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard&#xAE; Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Along with these core surgical products, AxoGen also offers AxoTouch</font><font style="display:inline;font-family:Calibri;font-size:6pt;top:-4pt;position:relative;line-height:100%">TM</font><font style="display:inline;font-family:Calibri;"> Two-Point Discriminator and AcroVal</font><font style="display:inline;font-family:Calibri;font-size:6pt;top:-4pt;position:relative;line-height:100%">TM</font><font style="display:inline;font-family:Calibri;"> Neurosensory &amp; Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function.&nbsp;The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Cautionary Statements Concerning Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2016 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom-style:solid;border-bottom-width:1pt;font-family:Calibri;color:#000000;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;"><font style="display:inline;font-family:Calibri;font-weight:bold;">Source:&nbsp;&nbsp;AxoGen, Inc.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">Contact:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">AxoGen, Inc.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Peter J. Mariani, Chief Financial Officer</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">386.462.6856</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">InvestorRelations@AxoGenInc.com&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">The Trout Group &#x2013; Investor Relations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Brian Korb</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">646.378.2923</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">bkorb@troutgroup.com&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>axgn20160916ex991b54ee5001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 axgn20160916ex991b54ee5001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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MB>+G,?A:^([JJ_FP']:VZQ?%L9E\+7RCLJM^3 _TK6A;VL;]T88J_L)V[/\
M(\E1&=U1!EF. !W)KT'PQIJ1ZHR8RMC&$)]96Y8_TKF_"%D+O74=QE(%,A^H
MZ5V7@XB2PNYSRTMTY8_C7IX^J[.*Z?J>#E=!<RF^OZ%OQ46'AJ^V]=G]:\CK
MV^ZMTN[62WD&4D4J?QKR?5_#M]I5PRM"TD.?DE09!']*C+:L8IP9MG%"<I*H
ME=%73=4N])N/.M9-I/#*>C?6NB_X6#?^7C[+#N_O9-<EL?IL;/TJ[::+J5\P
M%O9RG/\ $1@?F:[ZM*A)\T['F4*V)@N2G<L:AXEU34@5EN"L9_@CX%5]-TFZ
MU24B%0L:\O*_"J/<UTEMX/MM/A^UZW<JJ+SY:'K[9[U#<W5UKTZZ3I%O]GLQ
MU4#''JWI]*P5:"5J*LN_0Z'AZDFI5W=OIU*D=N+V<:-HP)C/_'Q<D<O_ (#V
MKT72=,@TJQ2U@7A1\S8Y8^IJ'1=%M]&M!#$,N>9)".6-:@KR\17YWRQV_,]O
M!X54ESRW_(6BBBN8[PIK$*"3T'6EKGO&&J_V=H[1HV)KCY%QV'<U=.#G)11E
M6JJE!S?0X3Q)JG]J:Q+(I_=1_)']!WK+2*27/EQL^.NT9IG:O3_!VEBRT5)9
M$'FSG><CH.U>[5JQPM))(^6H498VL[L\V^RW/_/O+_WP::UO.BEFAD51U)4B
MO;=B_P!T?E63XGC4^';WY1Q'GI7+#,G*27*=U3)U&#ES;'DE=S\/I0L=\C$
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
